Form 4: Abbott Laboratories Director Michael F. Roman Reports Stock Equivalent Unit Acquisition

Director Michael F. Roman reports acquisition of stock equivalent units in Abbott Laboratories due to director fees.

Summary

• On June 30, 2024, Michael F. Roman, a director of Abbott Laboratories, acquired 339 stock equivalent units as director fees.
• These units are credited to a stock equivalent unit account and are generally paid in cash at age 65 or upon retirement from the board.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
• The price of the stock equivalent units was $103.91.
• Following the transaction, Roman directly owns 4,009 stock equivalent units, which includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices for a director. There are no indications of negative events or concerns.

Industry Context

This filing is a routine disclosure of a director's acquisition of stock equivalent units, which is a common form of compensation for board members. It reflects standard corporate governance practices.

Stakeholder Impact

• The acquisition of stock equivalent units by a director aligns the director's interests with those of the shareholders.

Key Dates